Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052664 | 0.90 | RAB9A (0.55) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL1931817 | 0.85 | LMNA (0.58) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL3595449 | 0.85 | LMNA (0.58) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL17070011 | 0.83 | ALDH1A1 (0.50) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL5367181 | 0.83 | ALDH1A3 (0.61) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL9470287 | 0.83 | ALDH1A3 (0.52) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL123415 | 0.82 | MAPT (0.55) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL15335388 | 0.82 | ALDH1A3 (0.50) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL6836528 | 0.82 | ALDH1A3 (0.50) | ALDH1A3ALDH1A1CYP2A6SMN1; SMN2MAPT | |
| SCHEMBL6416510 | 0.82 | NPC1 (0.46) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271162-A | Preparation method of 4-isobutoxybenzylamine hydrochloride | 福建福瑞明德药业有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-106588753-B | Pimanerin preparation method | 重庆医药工业研究院有限责任公司 | 2021-07-09 | — | — | CN | claimed |
| CN-107200707-B | Preparation method of pimavanserin | 河北科技大学 | 2020-10-02 | — | — | CN | claimed |
| EP-3344603-B1 | A PRODUCTION METHOD OF 1-(4-FLUOROBENZYL)-3-(4-ISOBUTOXYBENZYL)-1-(1-METHYLPIPERIDIN- 4 YL)UREA AND ITS DEUTERATED ANALOGS NOT CONTAINING DIMERIC IMPURITIES | ZENTIVA KS (CZ) | 2020-09-30 | — | — | EP | claimed |
| CN-107011137-B | Synthetic method of pimavanserin intermediate | 杭州科耀医药科技有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-107216271-B | Tartaric acid Mo Fanselin impurity and preparation method thereof | 沈阳药科大学 | 2018-11-13 | — | — | CN | claimed |
| EP-3344603-A1 | A PRODUCTION METHOD OF 1-(4-FLUOROBENZYL)-3-(4-ISOBUTOXYBENZYL)-1-(1-METHYLPIPERIDIN- 4 YL)UREA AND ITS DEUTERATED ANALOGS NOT CONTAINING DIMERIC IMPURITIES | Zentiva, K.S. (CZ) | 2018-07-11 | — | — | EP | claimed |
| CN-107216271-A | Tartaric acid Mo Fanselin impurity and preparation method thereof | 沈阳药科大学 | 2017-09-29 | — | — | CN | claimed |
| CN-107011137-A | A kind of synthetic method of Mo Fanselin intermediate | 杭州科耀医药科技有限公司 | 2017-08-04 | — | — | CN | claimed |
| WO-2017036432-A1 | A PRODUCTION METHOD OF 1-(4-FLUOROBENZYL)-3-(4-ISOBUTOXYBENZYL)-1-(1-METHYLPIPERIDIN- 4— YL)UREA AND ITS DEUTERATED ANALOGS NOT CONTAINING DIMERIC IMPURITIES | ZENTIVA, K.S. (CZ) | 2017-03-09 | — | — | WO | claimed |
| EP-2289879-B1 | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt | ACADIA PHARM INC (US) | 2014-11-12 | — | — | EP | claimed |
| CN-102079731-A | Method for synthesizing 2-(3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazole formic acid | SHANGHAI HECHEN MEDICAL ENGINEERING CO LTD | 2011-06-01 | — | — | CN | claimed |
| US-7790899-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | claimed |
| CN-101778821-A | Synthesizing of N-(4-luorobenzyl)-N-(1-methyl piperidine-4-yl)-N '-(4-(2-methyl propoxy-) phenyl methyl) urea and tartrate and crystal formation | ACADIA PHARM INC | 2010-07-14 | — | — | CN | claimed |
| EP-2146960-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008144326-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | WO | claimed |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. | 2007-11-08 | — | — | US | claimed |
| CN-116354923-B | Nitrogen-containing heterocyclic compound and application thereof | 江苏恩华药业股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-4999186-A | P-aminobenzoic acid derivatives; chromogens | THE PROCTER & GAMBLE COMPANY (US) | 1991-03-12 | — | — | US | disclosed |
| EP-0255157-A2 | Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn | THE PROCTER & GAMBLE COMPANY (US) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | MTAP, CPN1, DNPEP | ALDH1A3 3803/4885ALDH1A1 3605/4885CYP2A6 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.